AU2018345221A1 - Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof - Google Patents
Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof Download PDFInfo
- Publication number
- AU2018345221A1 AU2018345221A1 AU2018345221A AU2018345221A AU2018345221A1 AU 2018345221 A1 AU2018345221 A1 AU 2018345221A1 AU 2018345221 A AU2018345221 A AU 2018345221A AU 2018345221 A AU2018345221 A AU 2018345221A AU 2018345221 A1 AU2018345221 A1 AU 2018345221A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- acceptable salt
- pharmaceutically acceptable
- nmr
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- IPNQMXXPEFBYOX-UHFFFAOYSA-N CCCCNC(c1cc(-c(cc2)ccc2C(OC(C)(C)C)=O)c(-c(cc2)ccc2OC)nc1)=O Chemical compound CCCCNC(c1cc(-c(cc2)ccc2C(OC(C)(C)C)=O)c(-c(cc2)ccc2OC)nc1)=O IPNQMXXPEFBYOX-UHFFFAOYSA-N 0.000 description 2
- LCQRVVKALYMIQR-UHFFFAOYSA-N COC(c1cc(N)c(-c(cc2)ccc2OC)nc1)=O Chemical compound COC(c1cc(N)c(-c(cc2)ccc2OC)nc1)=O LCQRVVKALYMIQR-UHFFFAOYSA-N 0.000 description 2
- BVSRQRORISPWLR-UHFFFAOYSA-N CC(C)(C)OC(c(cc1)ccc1-c1c(-c(cc2)ccc2OC)ncc(C(O)=O)c1)=O Chemical compound CC(C)(C)OC(c(cc1)ccc1-c1c(-c(cc2)ccc2OC)ncc(C(O)=O)c1)=O BVSRQRORISPWLR-UHFFFAOYSA-N 0.000 description 1
- CGGARRVLYXQNJH-UHFFFAOYSA-N CC(C)Cc1nc(-c(cc2)ccc2C(O)=C)c(-c(cc2C)cc(F)c2OC)nc1 Chemical compound CC(C)Cc1nc(-c(cc2)ccc2C(O)=C)c(-c(cc2C)cc(F)c2OC)nc1 CGGARRVLYXQNJH-UHFFFAOYSA-N 0.000 description 1
- XRUBCNQXLPTFPI-UHFFFAOYSA-N CC(c(ccc(-c1c(-c(cc2)ccc2OC)ncc(CCCOC)c1)c1)c1I)=O Chemical compound CC(c(ccc(-c1c(-c(cc2)ccc2OC)ncc(CCCOC)c1)c1)c1I)=O XRUBCNQXLPTFPI-UHFFFAOYSA-N 0.000 description 1
- VUSQZHKRYCXRRC-UHFFFAOYSA-N CC(c(ccc(-c1c(-c(cc2C)cc(F)c2OC)ncc(CCCOC)n1)c1)c1I)=O Chemical compound CC(c(ccc(-c1c(-c(cc2C)cc(F)c2OC)ncc(CCCOC)n1)c1)c1I)=O VUSQZHKRYCXRRC-UHFFFAOYSA-N 0.000 description 1
- FBAOFKFCKHJXRU-VOTSOKGWSA-N CC1(C)OB(/C=C/COC)OC1(C)C Chemical compound CC1(C)OB(/C=C/COC)OC1(C)C FBAOFKFCKHJXRU-VOTSOKGWSA-N 0.000 description 1
- 0 CC1(C=C(*)C(C)=CC(B(*)*)=C1)*(C)=N Chemical compound CC1(C=C(*)C(C)=CC(B(*)*)=C1)*(C)=N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N CC1CCNCC1 Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- KYINPWAJIVTFBW-UHFFFAOYSA-N CC1CNCC1 Chemical compound CC1CNCC1 KYINPWAJIVTFBW-UHFFFAOYSA-N 0.000 description 1
- LJPCNSSTRWGCMZ-UHFFFAOYSA-N CC1COCC1 Chemical compound CC1COCC1 LJPCNSSTRWGCMZ-UHFFFAOYSA-N 0.000 description 1
- KVEQAJJUWRLNLJ-UHFFFAOYSA-N CCCOCc1cc(-c(cc2)ccc2C(O)=C)c(-c(cc2)ccc2OC)nc1 Chemical compound CCCOCc1cc(-c(cc2)ccc2C(O)=C)c(-c(cc2)ccc2OC)nc1 KVEQAJJUWRLNLJ-UHFFFAOYSA-N 0.000 description 1
- UHWDRGOZEOIDFL-UHFFFAOYSA-N CCCOCc1cc(-c(cc2)ccc2C(O)=O)c(-c(cc2)ccc2OC)nc1 Chemical compound CCCOCc1cc(-c(cc2)ccc2C(O)=O)c(-c(cc2)ccc2OC)nc1 UHWDRGOZEOIDFL-UHFFFAOYSA-N 0.000 description 1
- QLEAHKFJURSUFV-UHFFFAOYSA-N CCCOCc1cc(-c(cc2)ccc2C(OC)=O)c(-c(cc2)ccc2OC)nc1 Chemical compound CCCOCc1cc(-c(cc2)ccc2C(OC)=O)c(-c(cc2)ccc2OC)nc1 QLEAHKFJURSUFV-UHFFFAOYSA-N 0.000 description 1
- MMJUKFFYCGUWSQ-UHFFFAOYSA-N CCOC(c(cc1)ccc1-c(nc(cn1)C#CCOC)c1O)=C Chemical compound CCOC(c(cc1)ccc1-c(nc(cn1)C#CCOC)c1O)=C MMJUKFFYCGUWSQ-UHFFFAOYSA-N 0.000 description 1
- VBMCFOPIVHKZPV-UHFFFAOYSA-N CCOC(c(cc1)ccc1-c(nc(cn1)I)c1O)=C Chemical compound CCOC(c(cc1)ccc1-c(nc(cn1)I)c1O)=C VBMCFOPIVHKZPV-UHFFFAOYSA-N 0.000 description 1
- IKKSIKVBKBKPBF-UHFFFAOYSA-N COC(c(cn1)cc(N)c1Br)=O Chemical compound COC(c(cn1)cc(N)c1Br)=O IKKSIKVBKBKPBF-UHFFFAOYSA-N 0.000 description 1
- LDJLFFHTWGGYLC-UHFFFAOYSA-N COC(c1cc(Br)c(-c(cc2)ccc2OC)nc1)=O Chemical compound COC(c1cc(Br)c(-c(cc2)ccc2OC)nc1)=O LDJLFFHTWGGYLC-UHFFFAOYSA-N 0.000 description 1
- VKCZMBFWVUYOQK-RMKNXTFCSA-N COC/C=C/c1cc(OCc2ccccc2)c(-c(cc2)ccc2OC)nc1 Chemical compound COC/C=C/c1cc(OCc2ccccc2)c(-c(cc2)ccc2OC)nc1 VKCZMBFWVUYOQK-RMKNXTFCSA-N 0.000 description 1
- UIVWADAYAVIWIC-UHFFFAOYSA-N COCCCc1cc(-c(cc2)ccc2C(OC)=O)c(-c(cc2)ccc2OC)nc1 Chemical compound COCCCc1cc(-c(cc2)ccc2C(OC)=O)c(-c(cc2)ccc2OC)nc1 UIVWADAYAVIWIC-UHFFFAOYSA-N 0.000 description 1
- XWVMUVUFSYZVPB-UHFFFAOYSA-N COCCCc1cc(O)c(-c(cc2)ccc2OC)nc1 Chemical compound COCCCc1cc(O)c(-c(cc2)ccc2OC)nc1 XWVMUVUFSYZVPB-UHFFFAOYSA-N 0.000 description 1
- XVFKXIZNEOKCMC-UHFFFAOYSA-N COCCCc1nc(-c(cc2)ccc2C(O)=O)c(-c(cc2F)cc(F)c2OC)nc1 Chemical compound COCCCc1nc(-c(cc2)ccc2C(O)=O)c(-c(cc2F)cc(F)c2OC)nc1 XVFKXIZNEOKCMC-UHFFFAOYSA-N 0.000 description 1
- JAMYWTCSWOLXHY-UHFFFAOYSA-N COCCCc1nc(-c(cc2)ccc2C(OC)=O)c(-c(cc2F)cc(F)c2OC)nc1 Chemical compound COCCCc1nc(-c(cc2)ccc2C(OC)=O)c(-c(cc2F)cc(F)c2OC)nc1 JAMYWTCSWOLXHY-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N COc1ccc(B(O)O)cc1 Chemical compound COc1ccc(B(O)O)cc1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- YYYXLQFZRWOYQK-UHFFFAOYSA-N Cc1cc(-c2c(-c(cc3)ccc3C(O)=C)nc(CCCOC)cn2)cc(F)c1OC Chemical compound Cc1cc(-c2c(-c(cc3)ccc3C(O)=C)nc(CCCOC)cn2)cc(F)c1OC YYYXLQFZRWOYQK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017194005 | 2017-10-04 | ||
| JP2017-194005 | 2017-10-04 | ||
| PCT/JP2018/037007 WO2019069973A1 (ja) | 2017-10-04 | 2018-10-03 | 含窒素ヘテロアリール化合物およびその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018345221A1 true AU2018345221A1 (en) | 2020-05-07 |
Family
ID=65994698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018345221A Abandoned AU2018345221A1 (en) | 2017-10-04 | 2018-10-03 | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10752596B2 (https=) |
| EP (1) | EP3693358B1 (https=) |
| JP (1) | JP7125882B2 (https=) |
| KR (1) | KR20200064101A (https=) |
| CN (1) | CN111148735B (https=) |
| AR (1) | AR113270A1 (https=) |
| AU (1) | AU2018345221A1 (https=) |
| BR (1) | BR112020004857A2 (https=) |
| CA (1) | CA3074989A1 (https=) |
| CL (1) | CL2020000898A1 (https=) |
| CO (1) | CO2020003977A2 (https=) |
| IL (1) | IL273573A (https=) |
| MX (1) | MX2020003816A (https=) |
| PE (1) | PE20200846A1 (https=) |
| PH (1) | PH12020550403A1 (https=) |
| RU (1) | RU2020115045A (https=) |
| SG (1) | SG11202003005PA (https=) |
| TW (1) | TW201922706A (https=) |
| WO (1) | WO2019069973A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110156698B (zh) * | 2019-06-06 | 2020-10-13 | 沈阳海诺威医药科技有限公司 | 2-苯基-1，6-二氢嘧啶-5-甲酸衍生物的制备方法和用途 |
| CN113181206B (zh) * | 2021-04-30 | 2023-07-14 | 青岛大学 | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 |
| IL313713A (en) * | 2022-01-07 | 2024-08-01 | Horizon Therapeutics Ireland Dac | Heterocyclic inhibitors of glut9 for treatment of disease |
| CN114805192B (zh) * | 2022-03-30 | 2023-05-23 | 华南理工大学 | 一种含2-羟基苯甲酸的三环类xor/urat1双重抑制剂及其制备方法与应用 |
| WO2024167952A1 (en) * | 2023-02-08 | 2024-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oxidatively cleavable organophosphate drugs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| IL127441A (en) * | 1996-07-18 | 2003-02-12 | Merck Frosst Canada Inc | Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors |
| PL343424A1 (en) * | 1998-04-10 | 2001-08-13 | Japan Tobacco Inc | Amidine compounds |
| WO2005013907A2 (en) * | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
| TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| JP2007176933A (ja) * | 2005-11-29 | 2007-07-12 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP5162827B2 (ja) | 2005-12-27 | 2013-03-13 | ぺんてる株式会社 | 鉛筆芯の製造方法 |
| JP5330990B2 (ja) | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
| JP2009016193A (ja) * | 2007-07-05 | 2009-01-22 | Daihen Corp | 電気機器用樹脂ブッシング |
| EP3594213A1 (en) * | 2009-07-17 | 2020-01-15 | Japan Tobacco Inc. | Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers |
| CA2794266C (en) | 2010-03-24 | 2020-09-08 | Ohio University | Compositions and methods for glucose transport inhibition |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| CN105439946B (zh) | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
| CN104306363B (zh) * | 2014-10-31 | 2017-06-06 | 南京葆赫生物技术有限公司 | 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用 |
-
2018
- 2018-10-03 KR KR1020207012149A patent/KR20200064101A/ko not_active Withdrawn
- 2018-10-03 JP JP2018188038A patent/JP7125882B2/ja active Active
- 2018-10-03 EP EP18864398.5A patent/EP3693358B1/en active Active
- 2018-10-03 CA CA3074989A patent/CA3074989A1/en not_active Abandoned
- 2018-10-03 AR ARP180102853A patent/AR113270A1/es unknown
- 2018-10-03 MX MX2020003816A patent/MX2020003816A/es unknown
- 2018-10-03 US US16/150,989 patent/US10752596B2/en active Active
- 2018-10-03 RU RU2020115045A patent/RU2020115045A/ru unknown
- 2018-10-03 TW TW107134941A patent/TW201922706A/zh unknown
- 2018-10-03 CN CN201880064738.0A patent/CN111148735B/zh active Active
- 2018-10-03 PE PE2020000529A patent/PE20200846A1/es unknown
- 2018-10-03 WO PCT/JP2018/037007 patent/WO2019069973A1/ja not_active Ceased
- 2018-10-03 SG SG11202003005PA patent/SG11202003005PA/en unknown
- 2018-10-03 BR BR112020004857-7A patent/BR112020004857A2/pt not_active Application Discontinuation
- 2018-10-03 AU AU2018345221A patent/AU2018345221A1/en not_active Abandoned
-
2020
- 2020-03-24 IL IL273573A patent/IL273573A/en unknown
- 2020-03-31 CO CONC2020/0003977A patent/CO2020003977A2/es unknown
- 2020-04-02 CL CL2020000898A patent/CL2020000898A1/es unknown
- 2020-04-06 PH PH12020550403A patent/PH12020550403A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10752596B2 (en) | 2020-08-25 |
| CA3074989A1 (en) | 2019-04-11 |
| SG11202003005PA (en) | 2020-04-29 |
| CN111148735B (zh) | 2023-08-08 |
| TW201922706A (zh) | 2019-06-16 |
| PE20200846A1 (es) | 2020-08-18 |
| PH12020550403A1 (en) | 2021-02-15 |
| JP2019065009A (ja) | 2019-04-25 |
| BR112020004857A2 (pt) | 2020-09-15 |
| RU2020115045A (ru) | 2021-11-08 |
| EP3693358B1 (en) | 2023-02-22 |
| EP3693358A1 (en) | 2020-08-12 |
| CL2020000898A1 (es) | 2020-08-14 |
| JP7125882B2 (ja) | 2022-08-25 |
| EP3693358A4 (en) | 2021-06-02 |
| CO2020003977A2 (es) | 2020-04-24 |
| US20190152926A1 (en) | 2019-05-23 |
| IL273573A (en) | 2020-05-31 |
| CN111148735A (zh) | 2020-05-12 |
| MX2020003816A (es) | 2020-08-13 |
| WO2019069973A1 (ja) | 2019-04-11 |
| AR113270A1 (es) | 2020-03-11 |
| KR20200064101A (ko) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3693358B1 (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
| KR101021828B1 (ko) | 2 이상의 치환기를 갖는 벤젠 화합물 | |
| US10195186B2 (en) | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | |
| KR102360699B1 (ko) | 트리아진 화합물 및 그의 의약 용도 | |
| TWI481604B (zh) | Novel 5-fluorouracil derivatives | |
| EP2563773A1 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites | |
| KR20030030382A (ko) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체 | |
| JP2021513966A (ja) | Ｔｒｐｃ６の阻害剤 | |
| JP2023536504A (ja) | Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物 | |
| TW201619146A (zh) | １－烷基－６－側氧基－１，６－二氫吡啶－３－基化合物及其用途 | |
| CN113784950A (zh) | 新型拟甲状腺素药 | |
| WO2005030773A1 (ja) | 新規ピラゾロピリミジン誘導体 | |
| AU2016309337A1 (en) | Hydroxytriazine compound and medical use thereof | |
| JP2005507381A (ja) | 心臓障害および代謝障害の治療のための主要環置換甲状腺受容体アンタゴニスト | |
| EP4110758A1 (en) | Heterocyclic compounds for modulating nr2f6 | |
| US9902709B2 (en) | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | |
| US20260083704A1 (en) | Lxr modulators with bicyclic core moiety for treating dyslipidemias | |
| US20210292315A1 (en) | Selenium-containing isoxazolamine compound, preparation method therefor, and use thereof | |
| JP2014198712A (ja) | フルオレン化合物の水和物、およびその結晶 | |
| WO2006109633A1 (ja) | 置換インドール化合物 | |
| KR19980701690A (ko) | 엔도텔린 길항제로서의 치환 페닐 화합물 | |
| HK40027595A (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
| JP7051109B2 (ja) | がん細胞にプログラム細胞死を誘導するための医薬組成物 | |
| HK40123212A (en) | Indazole compound and pharmaceutical use thereof | |
| WO2025144874A1 (en) | Potent nf-kb inhibitors for the treatment of inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |